272 related articles for article (PubMed ID: 15886257)
1. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
Betz MJ; Shapiro I; Fassnacht M; Hahner S; Reincke M; Beuschlein F;
J Clin Endocrinol Metab; 2005 Jul; 90(7):3886-96. PubMed ID: 15886257
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells.
Cerquetti L; Sampaoli C; Amendola D; Bucci B; Masuelli L; Marchese R; Misiti S; De Venanzi A; Poggi M; Toscano V; Stigliano A
Exp Cell Res; 2011 Jun; 317(10):1397-410. PubMed ID: 21376716
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
6. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
9. Selective effects of PPARgamma agonists and antagonists on human pre-adipocyte differentiation.
Leyvraz C; Suter M; Verdumo C; Calmes JM; Paroz A; Darimont C; Gaillard RC; Pralong FP; Giusti V
Diabetes Obes Metab; 2010 Mar; 12(3):195-203. PubMed ID: 19895635
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells.
Meshkani R; Sadeghi A; Taheripak G; Zarghooni M; Gerayesh-Nejad S; Bakhtiyari S
Cell Biochem Funct; 2014 Dec; 32(8):683-91. PubMed ID: 25431031
[TBL] [Abstract][Full Text] [Related]
11. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
12. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Al-Alem L; Southard RC; Kilgore MW; Curry TE
PLoS One; 2011 Jan; 6(1):e16179. PubMed ID: 21283708
[TBL] [Abstract][Full Text] [Related]
13. A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis.
Aires V; Brassart B; Carlier A; Scagliarini A; Mandard S; Limagne E; Solary E; Martiny L; Tarpin M; Delmas D
Mol Nutr Food Res; 2014 Sep; 58(9):1785-94. PubMed ID: 24975132
[TBL] [Abstract][Full Text] [Related]
14. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Fröhlich E; Machicao F; Wahl R
Endocr Relat Cancer; 2005 Jun; 12(2):291-303. PubMed ID: 15947104
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-γ ligands via Wnt signaling pathway.
Liu JJ; Dai XJ; Xu Y; Liu PQ; Zhang Y; Liu XD; Fang ZG; Lin DJ; Xiao RZ; Huang RW; Huang HQ
Cell Biochem Biophys; 2012 Jan; 62(1):19-27. PubMed ID: 21837368
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
18. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma.
Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH
Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Piaggi S; Gelmini S; Lupi C; Minuto M; Berti P; Benvenga S; Basolo F; Orlando C; Miccoli P
Endocr Relat Cancer; 2009 Dec; 16(4):1299-311. PubMed ID: 19755523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
